Thus, the expansion of CD117- ILC2s might be a phenomenon induced by Nivolumab regardless of the clinical outcome, but the survival benefit would depend on the effective capability of this subset to migrate from the periphery to the tumor in order to exert its anti-melanoma activity. Here, KIT is linked to melanoma.